Samalizumab

Drug Profile

Samalizumab

Alternative Names: ALXN 6000

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; The Leukemia & Lymphoma Society
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 03 Aug 2017 Alexion Pharmaceuticals suspends patient enrolment in a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02987504)
  • 27 Jul 2017 Samalizumab is available for licensing as of 27 Jul 2017. http://ir.alexionpharm.com/releasedetail.cfm?ReleaseID=1034669
  • 13 Dec 2016 Phase II trials in Acute myeloid leukaemia (Newly diagnosed, In the elderly) in USA (IV) before December 2016 (Alexion Pharmaceuticals Pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top